OPTIFLEX

Instructions

on medical use of medicinalfacilities

Trade name: Optiflex.
International nonproprietary name: Methylethylpyridinol.
Dosage form: Eye drops 1% - 10 ml.
Composition: *1 ml of the drug contains:*
Active substance: methylethylpyridinol hydrochloride 10.00 mg.
Excipients: disodium phosphate dodecahydrate, potassium dihydrogen phosphate, hypromellose, sodium benzoate, sodium sulfite anhydrous, water for injection.
Description: Transparent or slightly opalescent, colorless or brownish-yellow solution.
Pharmaco-therapeutic group: Ophthalmic drugs. Other drugs for the treatment of eye diseases. Antioxidant agent.
ATX code: S 01 XA.
Pharmacological properties:
Pharmacokinetics:
When using Optiflex eye drops, the active substance in biologically active concentrations does not enter the systemic circulation. Therapeutic concentration in the tissues of the eye is achieved with a single instillation. Methylethylpyridinol does not accumulate in organs and tissues. During the first two hours after use, the concentration of methylethylpyridinol in the blood decreases rapidly; after 24 hours there is no drug in the blood. In the tissues of the eye, the concentration of methylethylpyridinol is higher than in the blood.
Pharmacodynamics:
Angioprotector, reduces capillary permeability and strengthens the vascular wall, is an antioxidant, antihypoxant and antiplatelet agent .
Effectively inhibits free radical processes, has a membrane-stabilizing effect, and prevents lipid peroxidation of cell membranes. Increases tissue resistance to lack of oxygen. It has a beneficial effect on the blood coagulation system: it inhibits platelet aggregation, reduces the overall coagulation index, and lengthens blood clotting time. Strengthens the process of fibrinolysis.
It has retinoprotective properties, protects the retina and other eye tissues from the damaging effects of high-intensity light, promotes the resorption of intraocular hemorrhages, and improves microcirculation of the eye. Stimulates reparative processes in the cornea (including after surgery or injury).
Indications for use:
- treatment and prevention of inflammation and burns of the cornea;
- treatment of hemorrhages in the anterior chamber of the eye;
- treatment and prevention of hemorrhages in the sclera in elderly patients;
- thrombosis of the central retinal vein and its branches;
- treatment of complications of myopia (dystrophic changes in the retina);
- diabetic retinopathy;
- protection of the cornea (when wearing contact lenses);
- to protect the retina from exposure to high-intensity light (laser and sunburn, during laser coagulation).

Directions for use and dosage:
For topical use only.
The drug is instilled into the conjunctival sac, 1-2 drops 2-3 times a day. The duration of treatment depends on the course of the disease (usually 3-30 days) and is determined by the doctor. If necessary and well tolerated, the course of treatment can be extended to 6 months. The course of treatment can be repeated 2-3 times a year.
Avoid touching the tip of the dropper to any surfaces to avoid microbial contamination of the contents of the bottle.
Side effects:
Burning sensation, itching, short-term hyperemia of the conjunctiva, rarely - local allergic reactions.
Contraindications:
- hypersensitivity to methylethylpyridinol or other components of the drug;
- pregnancy and lactation period;
- children and adolescents up to 18 years of age.

Drug interactions:
negative effects have been described when using methylethylpyridinol during therapy with other drugs.
Special instructions:

If it is necessary to simultaneously use other ophthalmic drugs, Optiflex should be instilled last, after complete absorption of the previous drugs (at least 10-15 minutes).

Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms:

Patients who temporarily lose clarity of vision after using the drug should avoid potentially dangerous activities that require increased attention and speed of psychomotor reactions.

Overdose:

No cases of overdose have been reported.

Release form and packaging:

10 ml of the drug is placed in a plastic bottle with a dropper stopper and a screw-on protective cap equipped with a safety ring.

1 bottle along with instructions for medical use is placed in a cardboard pack.

Storage conditions:

Store at a temperature not exceeding 25 °C.

The period of use after opening the bottle is no more than 4 weeks.

Keep out of the reach of children!

Shelf life:

3 years.

Do not use after expiration date.

Conditions for dispensing from pharmacies

On prescription.

Made for:
MAXX PHARM LTD.
London, Great Britain